Docality.com Logo
 
Dr. Zuoheng  Fan  Md image

Dr. Zuoheng Fan Md

700 Oglethorpe Ave Suite B1
Athens GA 30606
706 531-1181
Medical School: Other - 1984
Accepts Medicare: Yes
Participates In eRX: Yes
Participates In PQRS: No
Participates In EHR: No
License #: 062337
NPI: 1770599912
Taxonomy Codes:
207RN0300X

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy

Conditions

Dr. Zuoheng Fan is associated with these group practices

Procedure Pricing

HCPCS Code Description Average Price Average Price
Allowed By Medicare
HCPCS Code:90960 Description:Esrd srv 4 visits p mo 20+ Average Price:$800.00 Average Price Allowed
By Medicare:
$268.97
HCPCS Code:99223 Description:Initial hospital care Average Price:$350.00 Average Price Allowed
By Medicare:
$187.25
HCPCS Code:90935 Description:Hemodialysis one evaluation Average Price:$220.00 Average Price Allowed
By Medicare:
$69.92
HCPCS Code:99233 Description:Subsequent hospital care Average Price:$225.00 Average Price Allowed
By Medicare:
$95.96
HCPCS Code:99238 Description:Hospital discharge day Average Price:$175.00 Average Price Allowed
By Medicare:
$66.51
HCPCS Code:99222 Description:Initial hospital care Average Price:$225.00 Average Price Allowed
By Medicare:
$127.51
HCPCS Code:99239 Description:Hospital discharge day Average Price:$195.00 Average Price Allowed
By Medicare:
$98.33
HCPCS Code:99205 Description:Office/outpatient visit new Average Price:$285.00 Average Price Allowed
By Medicare:
$188.50
HCPCS Code:99232 Description:Subsequent hospital care Average Price:$150.07 Average Price Allowed
By Medicare:
$66.89
HCPCS Code:99214 Description:Office/outpatient visit est Average Price:$175.00 Average Price Allowed
By Medicare:
$97.85
HCPCS Code:99215 Description:Office/outpatient visit est Average Price:$200.00 Average Price Allowed
By Medicare:
$131.76
HCPCS Code:J0885 Description:Epoetin alfa, non-esrd Average Price:$35.00 Average Price Allowed
By Medicare:
$9.71
HCPCS Code:81000 Description:Urinalysis nonauto w/scope Average Price:$22.00 Average Price Allowed
By Medicare:
$4.48

HCPCS Code Definitions

99232
Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is responding inadequately to therapy or has developed a minor complication. Typically, 25 minutes are spent at the bedside and on the patient's hospital floor or unit.
99223
Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the problem(s) requiring admission are of high severity. Typically, 70 minutes are spent at the bedside and on the patient's hospital floor or unit.
99222
Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the problem(s) requiring admission are of moderate severity. Typically, 50 minutes are spent at the bedside and on the patient's hospital floor or unit.
90935
Hemodialysis procedure with single evaluation by a physician or other qualified health care professional
90960
End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month
99215
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 40 minutes are spent face-to-face with the patient and/or family.
99214
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent face-to-face with the patient and/or family.
99205
Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 60 minutes are spent face-to-face with the patient and/or family.
99239
Hospital discharge day management; more than 30 minutes
99233
Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is unstable or has developed a significant complication or a significant new problem. Typically, 35 minutes are spent at the bedside and on the patient's hospital floor or unit.
99238
Hospital discharge day management; 30 minutes or less
J0885
Injection, epoetin alfa, (for non-esrd use), 1000 units

Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found

Referrals

NPI
Doctor Name
Specialty
Count
1205814548
Diagnostic Radiology
1,783
1770570871
Vascular Surgery
1,703
1366443640
Cardiovascular Disease (Cardiology)
1,628
1992784433
Emergency Medicine
1,231
1265400014
Cardiovascular Disease (Cardiology)
1,221
1083693048
Diagnostic Radiology
1,090
1700864055
Diagnostic Radiology
1,082
1568433407
General Practice
990
1306041900
Medical Oncology
986
1730150194
Interventional Pain Management
911
*These referrals represent the top 10 that Dr. Fan has made to other doctors

Publications

An autologous in situ tumor vaccination approach for hepatocellular carcinoma. 2. Tumor-specific immunity and cure after radio-inducible suicide gene therapy and systemic CD40-ligand and Flt3-ligand gene therapy in an orthotopic tumor model. - Radiation research
Diffuse hepatocellular carcinoma (HCC) is a lethal disease that radiation therapy (RT) currently has a limited role in treating because of the potential for developing fatal radiation-induced liver disease. However, recently diffuse HCC, "radio-inducible suicide gene therapy" has been shown to enhance local tumor control and residual microscopic disease within the liver for diffuse HCC, by using a combination of chemoactivation and molecular radiosensitization. We have demonstrated that the addition of recombinant adenovirus-expressing human Flt3 ligand (Adeno-Flt3L) after radio-inducible suicide gene therapy induced a Th1-biased, immune response and enhanced tumor control in an ectopic model of HCC. We hypothesized that sequential administration of recombinant adenovirus-expressing CD40L (Adeno-CD40L) could further potentiate the efficacy of our trimodal therapy with RT + HSV-TK + Adeno-Flt3L. We examined our hypothesis in an orthotopic model of diffuse HCC using BNL1ME A.7R.1 (BNL) cells in Balb/c mice. BNL murine hepatoma cells (5 × 10(4)) transfected with an expression vector of HSV-TK under the control of a radiation-inducible promoter were injected intraportally into BALB/cJ mice. Fourteen days after the HCC injection, mice were treated with a 25 Gy dose of radiation to the whole liver, followed by ganciclovir (GCV) treatment and systemic adenoviral cytokine gene therapy (Flt3L or CD40L or both). Untreated mice died in 27 ± 4 days. Radiation therapy alone had a marginal effect on survival (median = 35 ± 7 days) and the addition of HSV-TK/GCV gene therapy improved the median survival to 47 ± 6 days. However, the addition of Adeno-Flt3L to radiation therapy and HSV-TK/GCV therapy significantly (P = 0.0005) increased survival to a median of 63 ± 20 days with 44% (7/16) of the animals still alive 116 days after tumor implantation. The curative effect of Flt3L was completely abolished when using immunodeficient nude mice or mice depleted for CD4, CD8 and natural killer cells. The addition of Adeno-CD40L further improved the median survival of animals to 80 ± 15 days and this effect was abolished only when using anti-CD8 antibodies. Chromium-51 (51Cr) release assay showed cytotoxic T lymphocyte (CTL) activation, suggesting efficient dendritic cell (DC) activation with CTL activation after the treatment. Furthermore, when surviving mice were rechallenged with BNL-ETK cells on the foot pad, RT + HSV-TK/GCV + Flt3L + CD40L-treated mice developed a small tumor on day 56 but the tumor eventually disappeared after 105 days. Mice treated with RT + HSV-TK/GCV + Flt3L showed a slowed tumor growth curve compared with untreated mice. Therefore, combination therapy using Flt3L to induce DC proliferation and CD40L to enhance DC maturation holds great promise for immunomodulation of radiation therapy to enhance HCC tumor control and prevent progression of disease in patients with diffuse HCC.
Flt3L therapy following localized tumor irradiation generates long-term protective immune response in metastatic lung cancer: its implication in designing a vaccination strategy. - Oncology
Flt3 ligand (Flt3L) therapy that expands dendritic cells in vivo in combination with local tumor radiotherapy (RT) significantly improved survival and induced a long-term tumor-specific immune response in a murine model of Lewis lung carcinoma (3LL). The irradiated tumor cells were able to significantly restimulate the splenocytes of the RT + Flt3L cohort in vitro. The restimulated splenocytes demonstrated increased cytotoxic response, lymphocytic proliferation and elevated levels of Th type I cytokines (IL-2, IL-12, IFN-gamma and TNF-alpha). The combination therapy of RT + Flt3L induced a long-term protective immunity in the disease-free animals. The protective effect was further enhanced when the disease-free animals were vaccinated with irradiated tumor cells. The vaccinated animals had significantly greater protection compared to the nonvaccinated group against subsequent challenge with 3LL cells. Taken together, these results indicate that the release of tumor antigens by irradiated dying tumors and concomitant administration of Flt3L was able to facilitate the generation of a tumor-specific long-term immune response against a poorly immunogenic tumor. This effect was further boosted by vaccination with irradiated tumor cells.Copyright (c) 2006 S. Karger AG, Basel.
A candidate metastasis-associated DNA marker for ductal mammary carcinoma. - Breast cancer research : BCR
Molecular genetic markers to identify the 13% lymph node-negative mammary carcinomas that are prone to develop metastases would clearly be of considerable value in indicating those cases in need of early aggressive therapy.Representational difference analysis was used in an attempt to identify genetic alterations related to breast cancer metastasis by comparing genomic DNA from microdissected normal cells and from metastatic cells of ductal breast carcinoma patients.Representational difference analysis products yielded 10 unique metastasis-associated DNA sequences (MADS), i.e. products apparently lost in metastatic cell DNA. Of these sequences, MADS-IX was found to be lost in the transition from primary to metastasis in two out of five ductal breast carcinoma cases. This sequence was localized on chromosome 10q21 by radiation hybrid mapping and fluorescence in situ hybridization. The PTEN gene, which is also located on chromosome 10q, was detected to be present by PCR in all five cases. On the contrary, a breast carcinoma cell line, HCC-1937, which has homozygous loss of a region encompassing the PTEN gene, showed the presence of MADS-IX. PCR screening of three additional breast carcinoma cell lines with known losses in specific chromosomal regions also showed the presence of MADS-IX.These data suggest that MADS-IX possibly is part of a novel candidate metastasis-associated gene located close to the PTEN gene on chromosome 10q. The first set of PCR screening in five patient samples indicates that it could be used as a molecular marker for ductal mammary metastasis.

Map & Directions

700 Oglethorpe Ave Suite B1 Athens, GA 30606
View Directions In Google Maps

Nearby Doctors

225 Hawthorne Park
Athens, GA 30606
706 136-6136
1090 Founders Blvd Suite B
Athens, GA 30606
706 488-8697
117 Orion Pl
Athens, GA 30606
706 437-7194
2470 Daniels Bridge Rd Bldg 200 Suite 251
Athens, GA 30606
706 893-3440
1000 Hawthorne Avenue Suite J
Athens, GA 30606
706 694-4478
1230 Baxter St
Athens, GA 30606
706 893-3420
125 Telfair Pl
Athens, GA 30606
706 482-2454
1199 Prince Avenue
Athens, GA 30606
800 326-6151
700 Oglethorpe Ave Suite A-5
Athens, GA 30606
706 493-3110